메뉴 건너뛰기




Volumn 7, Issue 4, 2014, Pages 799-803

A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus

Author keywords

Blood lipid; Body weight; Hepatorenal function; Metformin; Type II diabetes mellitus; Vildagliptin

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN PLUS VILDAGLIPTIN; PLACEBO;

EID: 84896697835     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1545     Document Type: Article
Times cited : (9)

References (21)
  • 1
    • 82955247909 scopus 로고    scopus 로고
    • IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
    • Whiting DR, Guariguata L, Weil C and Shaw J: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321, 2011.
    • (2011) Diabetes Res Clin Pract , vol.94 , pp. 311-321
    • Whiting, D.R.1    Guariguata, L.2    Weil, C.3    Shaw, J.4
  • 2
    • 65449135133 scopus 로고    scopus 로고
    • Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    • Bosi E, Dotta F, Jia Y and Goodman M: Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 11: 506-515, 2009.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 506-515
    • Bosi, E.1    Dotta, F.2    Jia, Y.3    Goodman, M.4
  • 3
    • 77953192546 scopus 로고    scopus 로고
    • An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
    • Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A and Kothny W: An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 12: 495-509, 2010.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 495-509
    • Ligueros-Saylan, M.1    Foley, J.E.2    Schweizer, A.3    Couturier, A.4    Kothny, W.5
  • 4
    • 77949356196 scopus 로고    scopus 로고
    • A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study
    • Filozof C and Gautier JF: A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 27: 318-326, 2010.
    • (2010) Diabet Med , vol.27 , pp. 318-326
    • Filozof, C.1    Gautier, J.F.2
  • 5
    • 77955048324 scopus 로고    scopus 로고
    • Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study
    • Matthews DR, Dejager S, Ahren B, et al: Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12: 780-789, 2010.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 780-789
    • Matthews, D.R.1    Dejager, S.2    Ahren, B.3
  • 6
    • 78649711971 scopus 로고    scopus 로고
    • Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: A pooled analysis from a database of clinical trials
    • Schweizer A, Dejager S, Foley JE, Shao Q and Kothny W: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 13: 55-64, 2011.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 55-64
    • Schweizer, A.1    Dejager, S.2    Foley, J.E.3    Shao, Q.4    Kothny, W.5
  • 7
    • 84896729541 scopus 로고    scopus 로고
    • Safety and efficacy of vildagliptin: Dipeptidyl peptidase-4 inhibitor
    • Patel B and Shah J: Safety and efficacy of vildagliptin: dipeptidyl peptidase-4 inhibitor. IJPRBS 2: 35-51, 2012.
    • (2012) IJPRBS , vol.2 , pp. 35-51
    • Patel, B.1    Shah, J.2
  • 9
    • 75549091263 scopus 로고    scopus 로고
    • Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:An algorithm for glycemic control
    • Rodbard HW, Jellinger PS, Davidson JA, et al: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:an algorithm for glycemic control. Endocrine Practice 15: 540-549, 2009.
    • (2009) Endocrine Practice , vol.15 , pp. 540-549
    • Rodbard, H.W.1    Jellinger, P.S.2    Davidson, J.A.3
  • 10
    • 65449151804 scopus 로고    scopus 로고
    • The scientific evidence: Vildagliptin and the benefits of islet enhancement
    • Mathieu C: The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab 11 (Suppl 2): S9-S17, 2009.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.SUPPL. 2
    • Mathieu, C.1
  • 11
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. Glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • Ferrannini E, Fonseca V, Zinman B, et al: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11: 157-166, 2009.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3
  • 12
    • 34147093268 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    • Bosi E, Camisasca RP, Collober C, Rochotte E and Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890-895, 2007.
    • (2007) Diabetes Care , vol.30 , pp. 890-895
    • Bosi, E.1    Camisasca, R.P.2    Collober, C.3    Rochotte, E.4    Garber, A.J.5
  • 13
    • 36749024547 scopus 로고    scopus 로고
    • Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
    • Ahrén B, Pacini G, Tura A, Foley JE and Schweizer A: Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 39: 826-829, 2007.
    • (2007) Horm Metab Res , vol.39 , pp. 826-829
    • Ahrén, B.1    Pacini, G.2    Tura, A.3    Foley, J.E.4    Schweizer, A.5
  • 14
    • 37349054435 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin vs. Pioglitazone when added to metformin: A 24-week, randomized, double-blind study
    • Bolli G, Dotta F, Rochotte E and Cohen SE: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 10: 82-90, 2008.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 82-90
    • Bolli, G.1    Dotta, F.2    Rochotte, E.3    Cohen, S.E.4
  • 15
    • 65549131200 scopus 로고    scopus 로고
    • Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
    • Bolli G, Dotta F, Colin L, Minic B and Goodman M: Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 11: 589-595, 2009.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 589-595
    • Bolli, G.1    Dotta, F.2    Colin, L.3    Minic, B.4    Goodman, M.5
  • 16
    • 58149385790 scopus 로고    scopus 로고
    • Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting Islet-cell function in subjects with type 2 diabetes
    • D'Alessio DA, Denney AM, Hermiller LM, et al: Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting Islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94: 81-88, 2009.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 81-88
    • D'alessio, D.A.1    Denney, A.M.2    Hermiller, L.M.3
  • 17
    • 70349761649 scopus 로고    scopus 로고
    • Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: Results of the GALIANT trial - a primary care, type 2 diabetes study
    • Blonde L, Dagogo-Jack S, Banerji MA, et al: Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab 11: 978-986, 2009.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 978-986
    • Blonde, L.1    Dagogo-Jack, S.2    Banerji, M.A.3
  • 18
    • 78851471216 scopus 로고    scopus 로고
    • Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
    • Ahrén B, Foley JE and Bosi E: Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 13: 193-203, 2011.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 193-203
    • Ahrén, B.1    Foley, J.E.2    Bosi, E.3
  • 19
    • 82855179439 scopus 로고    scopus 로고
    • Tolerability of dipeptidyl peptidase-4 inhibitors: A review
    • Richard KR, Shelburne JS and Kirk JK: Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 33: 1609-1629, 2011.
    • (2011) Clin Ther , vol.33 , pp. 1609-1629
    • Richard, K.R.1    Shelburne, J.S.2    Kirk, J.K.3
  • 20
    • 80052551137 scopus 로고    scopus 로고
    • Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial
    • Lukashevich V, Schweizer A, Shao Q, Groop PH and Kothny W: Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13: 947-954, 2011.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 947-954
    • Lukashevich, V.1    Schweizer, A.2    Shao, Q.3    Groop, P.H.4    Kothny, W.5
  • 21
    • 79955506305 scopus 로고    scopus 로고
    • Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes
    • Kalra S: Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India 59: 237-245, 2011.
    • (2011) J Assoc Physicians India , vol.59 , pp. 237-245
    • Kalra, S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.